Clinical Trials Browser

masitinib × Plasma cell × Clear all

NCT00866138 2019-12-03

Masitinib in Relapse or Refractory Multiple Myeloma With t(4/14) Translocation Expressing or Not FGFR3

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT01470131 2018-12-19

A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

Phase 3 Terminated

Multiple Myeloma, Recurrence